Clear Scientific


Clinical-stage biopharmaceutical company developing highly selective small-molecule sequestrants to bind, inactivate, and accelerate clearance of toxic compounds. Focus areas include injectable and oral sequestrant therapeutics for acute intoxication (stimulants and opioids), preclinical and early-stage clinical development, analytical and formulation work, and collaborations with academic and clinical partners.

Industries

biotechnology

Nr. of Employees

small (1-50)

Clear Scientific

Cambridge, Massachusetts, United States, North America


Products

Injectable small-molecule sequestrant (lead clinical asset)

Injectable sequestrant formulation designed to bind intoxicants in blood and accelerate urinary clearance to rapidly reverse acute toxicity; progressed through Phase 1 and planned for Phase 2.

Oral sequestrant formulation (development-stage)

Orally delivered sequestrant designed to reduce gastrointestinal absorption of target compounds and limit brain exposure.

Expertise Areas

  • Sequestrant-based therapeutic development
  • Clinical trial management (early-stage)
  • Analytical and bioanalytical method development
  • Drug formulation and stability
  • Show More (4)

Key Technologies

  • Small-molecule sequestrants
  • Injectable therapeutic formulations
  • Oral sequestrant formulations
  • HPLC
  • Show More (6)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.